Nature-based solutions (NbS) contrast with grey infrastructure measures to reduce risk from natural hazards. Using natural and sustainable measures (green) or combining green with grey elements (hybrid) can provide important co-benefits beyond risk reduction. Thanks to their co-benefits and flexibility across a range of possible climate change futures, NbS are sometimes referred to as 'win-win' or 'no-regret' measures. The success of NbS and associated projects often relies on the public for co-creation, co-implementation, and long-term sustainable use, monitoring, and management. However, the relative importance of NbS benefits is defined by the perceptions and underlying values of stakeholders with potentially divergent interests. It is unclear what measures at-risk individuals may prefer on the green-hybrid-grey spectrum and what shapes their preferences, including perceived benefits and potential regret. Identifying public (mis)perceptions, expectations, objectives, and what underlies these can inform communication and project framing, engagement, and ultimately increase public acceptance and continued uptake of NbS. We use citizen surveys at three distinct European sites where NbS are being planned and in-depth focus groups as a follow-up in the site at risk of landslides (Catterline, Scotland). Preferences and their drivers for measures on the green-hybrid-grey spectrum are assessed, focusing on public perceptions of NbS effectiveness, risk, and nature. We find that although wildlife habitat and aesthetics as co-benefits are important, reducing risk is of primary concern. Uncertainty in the strength and effectiveness of NbS, as one of 13 qualitative factors we identify, drives public preferences towards hybrid measures - seen as balancing green and grey trade-offs. Misperceptions and a demand for NbS information should be addressed with experiential learning, combined with transparent two-way communication of expectations. We urge caution and further research regarding emphasizing co-benefits and the 'natural' framing of NbS when risk reduction is the primary public objective.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.jenvman.2022.114727 | DOI Listing |
JAMA Netw Open
January 2025
Department of Psychiatry, Harvard Medical School, Boston, Massachusetts.
Importance: During buprenorphine treatment for opioid use disorder (OUD), risk factors for opioid relapse or treatment dropout include comorbid substance use disorder, anxiety, or residual opioid craving. There is a need for a well-powered trial to evaluate virtually delivered groups, including both mindfulness and evidence-based approaches, to address these comorbidities during buprenorphine treatment.
Objective: To compare the effects of the Mindful Recovery Opioid Use Disorder Care Continuum (M-ROCC) vs active control among adults receiving buprenorphine for OUD.
J Travel Med
January 2025
UQ Centre for Clinical Research, Faculty of Health, Medicine, and Behavioural Sciences, The University of Queensland, Herston, Australia.
Background: Japanese encephalitis virus (JEV) is a leading cause of viral encephalitis in Asia, with high case-fatality rate and morbidity. Although the live recombinant Japanese encephalitis chimeric vaccine (Imojev®) offers strong initial immunity, data on long-term efficacy beyond five years remain limited.
Methods: We conducted a cross-sectional study on adults vaccinated with Imojev® at a specialist travel clinic in Brisbane, Australia.
Minerva Anestesiol
December 2024
Department of Anesthesiology, School of Medicine, Pontificia Universidad Católica de Chile, Santiago, Chile.
Background: Frail elderly patients have a higher risk of postoperative morbidity and mortality. Prehabilitation is a potential intervention for optimizing postoperative outcomes in frail patients. We studied the impact of a prehabilitation program on length of stay (LOS) in frail elderly patients undergoing elective surgery.
View Article and Find Full Text PDFPharmacol Rep
January 2025
Department of Pharmacy, The First People's Hospital of Changzhou/The Third Affiliated Hospital of Soochow University, Changzhou, 213003, Jiangsu, China.
Tacrolimus (TAC) is an immunosuppressant widely utilized in organ transplantation. One of its primary adverse effects is glucose metabolism disorder, which significantly increases the risk of diabetes. Investigating the molecular mechanisms underlying TAC-induced diabetes is essential for developing effective prevention and treatment strategies for these adverse effects.
View Article and Find Full Text PDFCardiovasc Drugs Ther
January 2025
Department of Medicine, Section of Cardiology, Baylor College of Medicine, 1 Baylor Plaza, Houston, TX, 77030, USA.
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!